Future studies will need to test FGF21 using in vivo models of ALS, including tissue-specific or systemic delivery, to validate the mitigating effects it appears to have in cellulo and to assess its potential as a novel therapy in ALS. Here, FGF21 is linked to amyotrophic lateral sclerosis.